Irvine, CA – PX1 Research has announced the launch of a new line of sublingual peptide strips designed for needle-free research applications. The dissolving strips, manufactured entirely within the United States under current Good Manufacturing Practice (cGMP) protocols, include formulations of Retatrutide, Tirzepatide, and BPC-157. This development marks a significant shift in how researchers can access these compounds, moving away from traditional injectable formats toward a non-invasive oral delivery method that meets stringent domestic quality standards.
According to the company, each strip undergoes High-Performance Liquid Chromatography (HPLC) purity verification, with results confirming 99% or greater purity across all formulations. Every product is accompanied by a Certificate of Analysis, providing researchers with documented evidence of batch composition before use. The domestic manufacturing approach underscores a broader emphasis on supply chain transparency, which is critical for researchers who require documentation trails that trace production conditions for institutional projects.
Among the available formulations, dissolving Retatrutide strips have drawn particular attention due to the compound's role in ongoing metabolic and weight regulation research. Tirzepatide and BPC-157 are also included, extending the line's applicability to glucose regulation and tissue repair studies, respectively. The sublingual delivery format allows the strip to dissolve under the tongue, enabling absorption without needles or syringes. This format addresses a logistical gap for research environments where non-invasive administration is a design requirement, whether due to protocol specifications, institutional review considerations, or participant-facing study designs.
PX1 Research has positioned these sublingual peptide strips specifically for academic and institutional research contexts. The strips are not intended for clinical, therapeutic, or human consumption use. Instead, the product meets demand from researchers who require compounds in a format compatible with non-invasive study designs, where traditional needle-based administration would introduce procedural variables or ethical complications.
The inclusion of BPC-157 alongside GLP-1 receptor agonist-class compounds such as Retatrutide and Tirzepatide signals the line's intent to serve a range of research disciplines. Each compound presents distinct molecular properties, and the sublingual strip format has been adapted to accommodate the specific stability and absorption characteristics relevant to each formulation.
The full product line is accessible through PX1 Research, with specific information on dissolving Retatrutide strips available directly on the product page. Researchers can also explore the broader offerings, which include other sublingual peptide strips and related compounds, all backed by HPLC purity verification and Certificates of Analysis.
PX1 Research, based in Irvine, California, is a US-based supplier of research-grade peptide formulations. The company's commitment to cGMP standards and domestic manufacturing ensures that researchers have access to high-quality, traceable compounds for their studies. This launch represents a step forward in expanding the toolkit available to the research community, potentially influencing study designs and outcomes in fields ranging from metabolic research to regenerative medicine.
